{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.564","value":"24.07"},{"groupId":"OG001","spread":"16.756","value":"19.23"},{"groupId":"OG002","spread":"17.266","value":"19.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"title":"Disease Symptoms: Baseline"},{"categories":[{"measurements":[{"comment":"Number of participants analyzed was one.","groupId":"OG000","spread":"NA","value":"0"},{"groupId":"OG001","spread":"7.384","value":"4.63"},{"groupId":"OG002","spread":"6.964","value":"3.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Disease Symptoms: Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"3.928","value":"2.78"},{"groupId":"OG002","spread":"3.928","value":"2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Disease Symptoms: Cycle 32"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.776","value":"16.67"},{"groupId":"OG001","spread":"14.464","value":"16.60"},{"groupId":"OG002","spread":"14.115","value":"16.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"title":"Side-Effects of Treatment: Baseline"},{"categories":[{"measurements":[{"comment":"Number of participants analyzed was one.","groupId":"OG000","spread":"NA","value":"3.70"},{"groupId":"OG001","spread":"3.825","value":"16.05"},{"groupId":"OG002","spread":"5.828","value":"14.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Side-Effects of Treatment: Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"15.713","value":"18.52"},{"groupId":"OG002","spread":"15.713","value":"18.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Side-Effects of Treatment: Cycle 32"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.542","value":"44.44"},{"groupId":"OG001","spread":"26.660","value":"23.08"},{"groupId":"OG002","spread":"30.058","value":"25.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"title":"Body Image: Baseline"},{"categories":[{"measurements":[{"comment":"Number of participants analyzed was one.","groupId":"OG000","spread":"NA","value":"0"},{"groupId":"OG001","spread":"18.257","value":"16.67"},{"groupId":"OG002","spread":"17.817","value":"14.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Body Image: Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"23.570","value":"16.67"},{"groupId":"OG002","spread":"23.570","value":"16.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Body Image: Cycle 32"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.185","value":"66.67"},{"groupId":"OG001","spread":"24.114","value":"44.16"},{"groupId":"OG002","spread":"26.817","value":"47.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"title":"Future Perspective: Baseline"},{"categories":[{"measurements":[{"comment":"Number of participants analyzed was one.","groupId":"OG000","spread":"NA","value":"11.11"},{"groupId":"OG001","spread":"8.364","value":"35.19"},{"groupId":"OG002","spread":"11.878","value":"31.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Future Perspective: Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"7.857","value":"27.78"},{"groupId":"OG002","spread":"7.857","value":"27.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Future Perspective: Cycle 32"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment). Scores are averaged, and transformed to 0-100 scale. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening.","dispersionType":"Standard Deviation","groups":[{"description":"Bortezomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG000","title":"[VRd]; Bortezomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG001","title":"[KRd]; Carfilzomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG002","title":"[Overall]; Combination Therapy + Ixazomib Therapy"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (FAS): all participants who were enrolled in Treatment Period I and who receive at least one dose of any therapy during the Treatment Period.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (Up to 23 cycles for VRd Group, Up to 32 cycles for KRd and Overall Group, each cycle was of 28 days)","title":"Patient-Reported Outcome HRQoL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Score","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}